Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling
Authors:
- Wei WeiWWWei Wei
- Sheng-Yu WangSWSheng-Yu Wang
- Zhi-Yan DuZDZhi-Yan Du
- Yuan-Ji XuYXYuan-Ji Xu
- Xiao-Dan YuXYXiao-Dan Yu
- 1 May 2008
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (9) , 1697-1705
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) Promotes Basal and Geldanamycin-Induced Degradation of Estrogen Receptor-αMolecular Endocrinology, 2005
- Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein KinaseJournal of Clinical Oncology, 2005
- Histone Deacetylase Inhibitors2004
- Histone deacetylase inhibitors in cancer therapyCancer Cell, 2003
- Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor ReceptorMolecular Endocrinology, 2003
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Biological Features of Premalignant Disease in the Human BreastJournal of Mammary Gland Biology and Neoplasia, 2000
- Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylationProceedings of the National Academy of Sciences, 2000
- Cross-resistance to different aromatase inhibitors in breast cancer treatment.Endocrine-Related Cancer, 1999
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast CancerJournal of Clinical Oncology, 1999